Radiopharmaceuticals in 2026: Inside the R&D Race, Regulatory Shifts, and the Isotope Supply Squeeze

Radiopharmaceuticals have moved from a specialist corner of oncology into one of pharma's most contested growth bets. Over the past two years the story has not been about market size alone, it has been about who controls the isotope supply chain, how far regulators will stretch existing radioligand approvals, and which manufacturers can actually deliver a short-half-life radioactive product to a clinic on time. This piece looks past the sizing numbers covered in our companion market report and focuses on the research, regulatory, and industrial developments that are actually shaping the sector through 2026.

A Record Two Years of Dealmaking

Big pharma's pivot to targeted radiation therapy has been the defining corporate story of the sector since 2024. Novartis, already the category leader with Pluvicto and Lutathera, added a $1.75 billion bet on Mariana Oncology (up to $1 billion upfront plus $750 million in milestones). Eli Lilly followed its 2021 purchase of Point Biopharma with a $1.4 billion deal and a further collaboration with Aktis Oncology, while Bristol Myers Squibb paid $4.1 billion for RayzeBio and AstraZeneca committed $2 billion to Fusion Pharmaceuticals, according to deal disclosures tracked by Labiotech and FiercePharma.

That run was eclipsed in August 2026, when Curium, the CapVest-backed nuclear medicine manufacturer, agreed to acquire Nasdaq-listed Lantheus in a deal worth up to $8 billion, $102.50 a share in cash plus up to $12 a share in contingent value rights tied to sales milestones through 2030. FierceBiotech and Chinese business outlet 36Kr both flagged it as the largest M&A transaction in radiopharmaceutical-sector history, merging Curium's global isotope-manufacturing network with Lantheus's U.S. commercial franchise (Pylarify, Definity, Neuraceq). Curium CEO Renaud Dehareng called Lantheus “the ideal partner that accelerates the integrated diagnosis and treatment platform we have been building,” with the combined entity expected to close in the first half of 2027. Venture funding followed the same trajectory: ITM Radiopharma, Abdera Therapeutics, Convergent Therapeutics, Ratio Therapeutics and Radionetics Oncology collectively raised well over $500 million in 2024 alone, per Labiotech's review of the year's financings.

Regulatory Momentum: What FDA and EMA Have Actually Approved

The clearest sign of regulatory confidence in radioligand therapy came on March 28, 2025, when the FDA expanded Pluvicto's label to PSMA-positive metastatic castration-resistant prostate cancer patients who have had one androgen-receptor-pathway inhibitor and can appropriately delay chemotherapy, roughly tripling the eligible patient pool. The approval rested on the Phase III PSMAfore trial, which showed a 59% reduction in the risk of radiographic progression or death versus switching ARPIs (HR 0.41, p<0.0001; median radiographic progression-free survival of 11.6 months versus 5.6 months). “This approval is a significant step forward and should open the doorway to a therapy with clear clinical advantages,” said Michael Morris, MD, prostate cancer section head at Memorial Sloan Kettering, while Oliver Sartor, MD, director of radiopharmaceutical clinical trials at Mayo Clinic, pointed to “clear clinical benefit in delaying disease progression.” Novartis U.S. president Victor Bultó framed it plainly: the approval “brings more choice to nearly three times as many patients.”

The FDA has moved on parallel tracks elsewhere in the category: Telix's Illuccix imaging agent picked up a pre-taxane label expansion, a Lu-177 dotatate radioequivalent received tentative approval for gastroenteropancreatic neuroendocrine tumors, and the agency has been developing dosage-optimization guidance specific to oncology radiopharmaceuticals in clinical development, extending its broader Project Optimus dose-finding push into the isotope space. In Europe, policymakers have focused less on individual approvals and more on supply resilience: the Council of the EU formally approved conclusions on securing the medical radioisotope supply chain in June 2024, and the European Commission's Critical Medicines Alliance, launched that January, now treats radioisotopes as a named priority category.

Source: Novartis media release (Mar 28, 2025); Targeted Oncology; OncologyNewsCentral; Council of the European Union (Consilium), press release, June 17, 2024; European Commission, energy.ec.europa.eu; FDA.gov guidance database.

The Isotope Bottleneck Nobody Talks About

None of this dealmaking or label expansion matters if manufacturers cannot secure the isotopes themselves. Actinium-225, the alpha-emitter behind much of the next-generation targeted radiotherapy pipeline, has been supplied for nearly three decades almost entirely by Oak Ridge National Laboratory, which extracts it from 1940s- and 1950s-era thorium-229 stockpiles. That single-source dependency became visible in 2024, when a supply shortage forced Bristol Myers Squibb's RayzeBio to pause a Phase 3 trial, according to reporting by BioSpace. A wave of new producers has since raced in: NorthStar Medical Radioisotopes says it has achieved the first commercial-scale non-carrier-added Ac-225 production using electron-accelerator technology; BWXT Medical is producing at Canada's TRIUMF facility; Niowave is using a superconducting electron linear accelerator; Eckert & Ziegler is pursuing a cyclotron-based route; and TerraPower Isotopes is working with Isotek to recover thorium-229 from the U.S. Department of Energy's uranium-233 stockpile.

Pharma has responded by locking down multi-year, often multi-supplier contracts. AstraZeneca signed a 10-year actinium-225 supply agreement with Niowave in December 2024; Bayer has spread its sourcing across BWXT, Ionetix, NorthStar and PanTera since 2022; and Eli Lilly, having partnered with Ionetix through its Point Biopharma acquisition in 2021, took an equity stake in Ionetix in 2024. “The decision goes beyond the pure technical aspect, which we value, and is ultimately a holistic business case,” NorthStar CEO Frank Scholz said of the sourcing calculus drug developers now face.

Source: BioSpace, “Radiopharma Sector Races To Secure Actinium-225 Supply as Pipelines Expand”; company press releases.

Europe's Policy Response: Building Isotope Sovereignty

European regulators and clinicians have been the loudest about supply fragility. The European Association of Nuclear Medicine has repeatedly warned that “timely production and delivery are critical, and any disruption can seriously affect patient care and clinical outcomes,” and has pushed for more transparent, better-communicated supply chains between producers, hospitals and regulators. The European Commission's SAMIRA Action Plan has since spawned the European Radioisotope Valley Initiative, intended to “maintain Europe's global leadership in the supply of medical radioisotopes,” with feasibility studies underway ahead of any binding legal framework. It builds on the longer-running European Observatory on the Supply of Medicinal Radioisotopes, in place since 2012 to safeguard the Mo-99/Tc-99m generator supply that most diagnostic nuclear medicine still depends on.

Regional Spotlight: India's Nuclear Medicine Buildout

Away from the U.S. and EU deal headlines, India has quietly become one of the fastest-scaling nuclear medicine markets, and was named a “highlight country” at the Society of Nuclear Medicine and Molecular Imaging's 2023 Annual Meeting. According to a review published in the Indian Journal of Nuclear Medicine, the country's infrastructure now includes:

• 442 operating nuclear medicine centers nationwide

• 359 PET-CT scanners in service, including three PET/MR hybrid units

• 24 functional medical cyclotrons

• 150 high-dose radionuclide therapy facilities

The same review estimates India needs roughly 1,000 additional PET-CT scanners over the next decade just to reach a ratio of one scanner per million population, a scale-up problem the government is attacking on the supply side. The Board of Radiation and Isotope Technology (BRIT) supplies radiopharmaceuticals and generators, while the Bhabha Atomic Research Centre develops indigenous isotopes using the upgraded APSARA-U research reactor. A dedicated public-private reactor project (₹250 crore, roughly $30 million) and a LINAC-based alternative route to Mo-99/Tc-99m production (₹100 crore, roughly $13 million, funded by the Ministry of Electronics and Information Technology) are both underway, alongside a “Fission Moly Plant” for high-specific-activity Mo-99. Roughly 25 institutions now graduate about 50 MD/DNB physicians and 150 technologists into the field each year, a pipeline India will need if it is to close the scanner gap on schedule.

What to Watch Through 2027

Three threads are worth tracking as the Curium-Lantheus deal moves toward its expected first-half-2027 close: whether further consolidation follows among mid-size radiopharma players still without a captive isotope supply; whether the new wave of accelerator- and reactor-based actinium-225 producers can scale fast enough to keep pace with an expanding late-stage pipeline; and whether the EU's European Radioisotope Valley Initiative converts its feasibility studies into an actual legal and funding framework before the next supply disruption forces the issue. For now, the isotope supply chain, not clinical efficacy, remains the industry's binding constraint.

Related Vectomat Insights Coverage

This article provides editorial and R&D context only. For full market sizing, segmentation, regional share, competitive benchmarking and forecasts through 2035, see the companion Radiopharmaceuticals Market Report.